Cargando…

Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma

BACKGROUND: Exposure–response analyses were conducted to explore the relationship between selected efficacy and safety endpoints and serum phosphate (PO4) concentrations, a potential biomarker of efficacy and safety, in locally advanced or metastatic urothelial carcinoma patients with FGFR alteratio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dosne, Anne-Gaëlle, Valade, Elodie, Goeyvaerts, Nele, De Porre, Peter, Avadhani, Anjali, O’Hagan, Anne, Li, Lilian Y., Ouellet, Daniele, Perez Ruixo, Juan Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807442/ https://www.ncbi.nlm.nih.gov/pubmed/34977972 http://dx.doi.org/10.1007/s00280-021-04381-4

Ejemplares similares

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer
por: Dosne, Anne‐Gaëlle, et al.
Publicado: (2021)

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
por: Rouvinov, Keren, et al.
Publicado: (2023)

Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
por: Sayegh, Nicolas, et al.
Publicado: (2022)

Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program
por: Monteiro, Fernando Sabino M., et al.
Publicado: (2021)

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib
por: Sarkisian, Saro, et al.
Publicado: (2020)

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis
por: Zheng, Xinyi, et al.
Publicado: (2023)

Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib
por: Deutsch, Alana, et al.
Publicado: (2020)

Calciphylaxis associated with the fibroblast growth factor receptor inhibitor erdafitinib
por: Macklis, Paul, et al.
Publicado: (2020)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment
por: Wang, Songbai, et al.
Publicado: (2020)

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
por: Ruan, Lan-hong, et al.
Publicado: (2021)

Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report
por: Ding, Xinjia, et al.
Publicado: (2021)

Precision medicine: Sustained response to erdafitinib in FGFR2 ‐mutant, multiply recurrent ameloblastoma
por: Lawson‐Michod, Katherine A., et al.
Publicado: (2022)

A strategy for residual error modeling incorporating scedasticity of variance and distribution shape
por: Dosne, Anne-Gaëlle, et al.
Publicado: (2015)

dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap
por: Dosne, Anne-Gaëlle, et al.
Publicado: (2016)

An automated sampling importance resampling procedure for estimating parameter uncertainty
por: Dosne, Anne-Gaëlle, et al.
Publicado: (2017)

Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020)

Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling
por: Dosne, Anne-Gaëlle, et al.
Publicado: (2016)

Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
por: de Almeida Carvalho, Lelia Maria, et al.
Publicado: (2019)

TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
por: Stepien, Natalia, et al.
Publicado: (2023)

Model structure analysis to estimate basic immunological processes and maternal risk for parvovirus B19
por: Goeyvaerts, Nele, et al.
Publicado: (2011)

Metastatic urothelial carcinoma()()
por: Gómez-Moyano, Elisabeth, et al.
Publicado: (2021)

MetMaxStruct: A Tversky-Similarity-Based Strategy for Analysing the (Sub)Structural Similarities of Drugs and Endogenous Metabolites
por: O'Hagan, Steve, et al.
Publicado: (2016)

Review of Statistical Methods for Analysing Healthcare Resources and Costs
por: Mihaylova, Borislava, et al.
Publicado: (2011)

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
por: Schlotman, Alyssa, et al.
Publicado: (2020)

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report
por: Pham, Chi, et al.
Publicado: (2023)

Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib
por: De Zwart, Loeckie, et al.
Publicado: (2021)

Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor
por: Meng, Xinmin, et al.
Publicado: (2022)

Update on the Treatment of Metastatic Urothelial Carcinoma
por: Bukhari, Nedal, et al.
Publicado: (2018)

Mining social mixing patterns for infectious disease models based on a two-day population survey in Belgium
por: Hens, Niel, et al.
Publicado: (2009)

Complexity of FGFR signalling in metastatic urothelial cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Role of surgical consolidation in metastatic urothelial carcinoma
por: Abe, Takashige, et al.
Publicado: (2016)

CASE OF METASTATIC UROTHELIAL CARCINOMA OF THE RETINA AND VITREOUS
por: Whalen, Katherine E., et al.
Publicado: (2018)

Metastatic urothelial carcinoma presenting as acute cholecystitis
por: Ling, Xing Yao, et al.
Publicado: (2019)

Emerging agents for the treatment of metastatic urothelial cancer
por: Kwon, Whi-An, et al.
Publicado: (2021)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
por: Katims, Andrew B., et al.
Publicado: (2022)

Cutaneous metastasis as a complication of hepatic intra-arterial chemotherapy.
por: O'Hagan, S., et al.
Publicado: (1997)

Themed series in organo-fluorine chemistry
por: O'Hagan, David
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_81neg7i3da18j51vnq3s096nnr